equitymaster.comFalseFalseBALAXI PHARMA |
|
Price History |
Price | Rs | 496.0 | | % ch | % | 1.4 |
Mkt Cap | Rs m | 5,405 | | No. of
shares | m | 10.90 |
Vol | '000 | 10.6 | | % ch week | % | 2.4 |
P/E | X | -103.5 | | % ch 1-mth | % | -20.0 |
P/CF | X | 11.3 | | % ch 12-mth | % | -6.8 |
EPS (TTM) | Rs | -4.8 | | 52 week H/L | Rs | 686.3/400.0 |
(As on Mar 28, 2024 (Close)) |
|
Financials |
* Results Consolidated | No. of Months
Year Ending | 12
Mar-19* | 12
Mar-20* | 12
Mar-21* | 12
Mar-22* | 12
Mar-23* |
EQUITY SHARE DATA |
High | Rs | NA | NA | NA | 700 | 706 |
Low | Rs | NA | NA | NA | 342 | 304 |
Sales per share (Unadj.) | Rs | 44.7 | 45.6 | 231.3 | 279.4 | 330.5 |
Earnings per share (Unadj.) | Rs | 6.5 | 6.1 | 38.1 | 47.7 | 45.2 |
Diluted earnings per share | Rs | 1.8 | 5.6 | 35.0 | 43.7 | 42.2 |
Cash flow per share (Unadj.) | Rs | 6.5 | 6.1 | 38.4 | 48.2 | 46.9 |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0.50 | 0 |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.46 | 0.00 |
Avg Dividend yield | % | 0 | 0 | 0 | 0.1 | 0 |
Book value per share (Unadj.) | Rs | 11.6 | 27.7 | 65.0 | 113.2 | 169.5 |
Adj. book value per share | Rs | 3.2 | 25.5 | 59.6 | 103.8 | 158.4 |
Shares outstanding (eoy) | m | 3.04 | 10.00 | 10.00 | 10.00 | 10.18 |
Bonus / Rights / Conversions | | 0 | 0 | 0 | 0 | 0 |
Price / Sales ratio | x | 0 | 0 | 0 | 1.9 | 1.5 |
Avg P/E ratio | x | 0 | 0 | 0 | 10.9 | 11.2 |
P/CF ratio (eoy) | x | 0 | 0 | 0 | 10.8 | 10.8 |
Price / Book Value ratio | x | 0 | 0 | 0 | 4.6 | 3.0 |
Dividend payout | % | 0 | 0 | 0 | 1.0 | 0 |
Avg Mkt Cap | Rs m | 0 | 0 | 0 | 5,208 | 5,139 |
No. of employees | `000 | NA | NA | NA | NA | NA |
Total wages/salary | Rs m | 9 | 21 | 85 | 125 | 290 |
Avg. sales/employee | Rs Th | 0 | 0 | 0 | 0 | 0 |
Avg. wages/employee | Rs Th | 0 | 0 | 0 | 0 | 0 |
Avg. net profit/employee | Rs Th | 0 | 0 | 0 | 0 | 0 |
INCOME DATA |
Net Sales | Rs m | 136 | 456 | 2,313 | 2,794 | 3,364 |
Other income | Rs m | 9 | 6 | 22 | 50 | 26 |
Total revenues | Rs m | 145 | 462 | 2,336 | 2,844 | 3,391 |
Gross profit | Rs m | 16 | 83 | 427 | 508 | 574 |
Depreciation | Rs m | 0 | 0 | 3 | 5 | 18 |
Interest | Rs m | 0 | 0 | 3 | 8 | 14 |
Profit before tax | Rs m | 24 | 88 | 443 | 545 | 569 |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 |
Tax | Rs m | 5 | 27 | 62 | 69 | 110 |
Profit after tax | Rs m | 20 | 61 | 381 | 477 | 460 |
Gross profit margin | % | 11.5 | 18.1 | 18.4 | 18.2 | 17.1 |
Effective tax rate | % | 19.4 | 30.6 | 14.0 | 12.6 | 19.3 |
Net profit margin | % | 14.5 | 13.4 | 16.5 | 17.1 | 13.7 |
BALANCE SHEET DATA |
Current assets | Rs m | 58 | 349 | 938 | 1,410 | 1,935 |
Current liabilities | Rs m | 26 | 82 | 347 | 633 | 531 |
Net working cap to sales | % | 23.5 | 58.4 | 25.5 | 27.8 | 41.7 |
Current ratio | x | 2.2 | 4.2 | 2.7 | 2.2 | 3.6 |
Inventory Days | Days | 9 | 7 | 5 | 8 | 2 |
Debtors Days | Days | 146,964 | 2,377 | 1,211 | 360 | 567 |
Net fixed assets | Rs m | 3 | 11 | 59 | 355 | 462 |
Share capital | Rs m | 30 | 100 | 100 | 100 | 102 |
"Free" reserves | Rs m | 5 | 177 | 550 | 1,032 | 1,624 |
Net worth | Rs m | 35 | 277 | 650 | 1,132 | 1,726 |
Long term debt | Rs m | 0 | 0 | 0 | 0 | 9 |
Total assets | Rs m | 61 | 360 | 997 | 1,765 | 2,397 |
Interest coverage | x | 1,221.0 | 184.2 | 160.5 | 72.6 | 42.3 |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 |
Sales to assets ratio | x | 2.2 | 1.3 | 2.3 | 1.6 | 1.4 |
Return on assets | % | 32.2 | 17.1 | 38.5 | 27.4 | 19.8 |
Return on equity | % | 55.8 | 22.0 | 58.7 | 42.1 | 26.6 |
Return on capital | % | 69.3 | 31.9 | 68.6 | 48.9 | 33.6 |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 |
Fx inflow | Rs m | 136 | 456 | 869 | 1,000 | 802 |
Fx outflow | Rs m | 0 | 10 | 110 | 87 | 40 |
Net fx | Rs m | 136 | 447 | 759 | 913 | 763 |
CASH FLOW |
From Operations | Rs m | -15 | -140 | 0 | 341 | 61 |
From Investments | Rs m | -0 | -2 | -60 | -284 | -106 |
From Financial Activity | Rs m | 0 | 181 | 36 | -2 | 255 |
Net Cashflow | Rs m | -15 | 39 | -23 | 55 | 210 |
* Results Consolidated | Source: Company Annual Reports, Regulatory Filings, Equitymaster |
|
Share Holding |
Indian Promoters: | 71.2% |
Foreign collaborators: | 0.0% |
Indian inst/Mut Fund: | 18.6% |
FIIs: | 18.6% |
ADR/GDR: | 0.0% |
Free float: | 28.8% |
Shareholders: | 5,045 |
Pledged promoter(s) holding: | 0.0% |
|
Company Information |
REGD OFF: | Plot No. 409 H. No. 8-2-293, Maps Towers 3rd Floor Phase I I I, Road No. 81 Jubilee Hills, Hyderabad - 500096 |
E-MAIL: | info@balaxi.in |
WEB: | www.balaxipharma.in |
TELEPHONE: | 040 23555300 |
FAX: | |
SECTOR: | TRADING |
GROUP: | Private sector |
TR AGENT: | Aarthi Consultants Pvt Ltd, 1-2-285, Domalaguda |
CHM: | Ashish Maheshwari |
COMP SEC: | Nidhin Jose |
YEAR OF INC: | 1942 |
NSE CODE: | 98563236 |
FV (Rs): | 10 |
DIV YIELD (%): | - |